Integra Therapeutics has been awarded a €335,000 non-refundable grant through the Spanish Ministry of Science and Innovation Neotec programme, managed by the Centre for the Development of Industrial Technology (CDTI).

Neotec is a highly competitive programme that aims to foster technology and innovation for the development of companies based in Spain. In the 2022 call, the programme awarded grants to 135 projects. In this regard, it is significant that the Integra Therapeutics research project was among the top 20 because it highlights the company’s solid business model and the importance of developing more precise and effective advanced therapies for patients and the healthcare systems.

The grant will allow the company to continue the implementation of its FiCAT gene-writing platform for viral-free in vivo delivery to liver cells for gene therapy and generation of proof of concept data on its first therapeutic product, which will run until 2024.

The company will also reinforce its R&D team, hiring two senior scientists with a strong background protein engineering and bioinformàtics, respectively. Integra Therapeutics currently has a team of 13 highly qualified professionals at its headquarters in the Barcelona Biomedical Research Park (PRBB).

In addition to the grant, Integra Therapeutics will be able to take part in a training programme on Entrepreneurship, Innovation and Sustainability at the Georgia Institute of Technology in Atlanta (USA).

Integra Therapeutics is a global leader in creating next-generation gene-writing tools to make advanced therapies safer and more effective. Since it was established in 2020, the company has secured €8 million in venture capital (AdBio Partners, Columbus Venture Partners, Invivo Capital and Takeda Ventures) and through various competitive programmes of the European Union, Spanish Government and Government of Catalonia.